Dyve Biosciences

Dyve Biosciences is proud to announce FDA clearance to initiate phase 2 study of DYV-700 for treatment of acute #gout pain. Full press release: tinyurl.com/qk4vtzm

Dyve’s science has demonstrated the power to deliver up to 40% of the applied dose into the blood, which exceeds what is seen by many pills. #biotech

Thank you to @MassDevice for highlighting Dyve's press release announcing first patient enrollment in Phase 2 TARGETS Study for Acute Gout: bit.ly/2PcQfiu #gout #biotech #clinicaltrials

Thank you @Machiz and @Nasdaq for featuring Dyve in their #NasdaqSpotlight series in New York City last week! You can view the full interview with CEO Ryan Beal on Dyve's website: bit.ly/38LLx2M #biotech #healthcare

First subjects were enrolled in Dyve's Phase 2 TARGETS study this week! Thank you to all of our partners for making this achievement possible. It is an exciting milestone for our company! #gout #biotech

We had an exciting week in New York! Thank you to @IAmBiotech for hosting #BIOCEO20 as well as @Nasdaq for highlighting Dyve on #NasdaqSpotlight! #biotech

Thanks to @byndergroup for their continued partnership and the amazing work they've put into developing our website! dyvebio.com

BIO is helping leaders fulfill that commitment by providing resources to help build a more inclusive and diverse workforce. Learn more at buff.ly/2S3JkIT #rightmixmatters

@mikewill91 Thanks, Mike!

@DyveBio Congratulations!

Dyve is thrilled to welcome longtime Pfizer Executive Chuck Harbert, Ph.D. to the company in the role of Chief Scientific Officer. Full press release: tinyurl.com/yexnmx99 Learn more about Dyve: dyvebio.com

Gout flares are characterized by the formation of sodium urate crystals in the joint space, causing intense pain typically lasting 48-96 hours.

@mikewill91 Thanks for the interest @mikewill91! You can get in touch with us through our contact page: dyvebio.com/contact and someone from our team will reach out to connect.

@DyveBio Let’s work together!

DYV-700 was recently approved for phase 2 trial for treatment of acute gout pain. Here's why we're excited.

.@DyveBio wins FDA nod for Phase 2 transdermal drug delivery trial bit.ly/2PpPnYc

@mikewill91 Thank you, Mike!

@DyveBio Congratulations!

@sclinical Thank you for your interest! We will share your contact info with the team and will reach out if it seems like a good fit.

@DyveBio Congratulations, Dr. Beal on receiving FDA clearance for DYV-700. I represent SC Research. We are very interested in being a research site for your Phase 2 study of DYV-700. Our PI has 10 years of Gout trial experience. Our contact info is suburbanclinical@yahoo.com.

Dyve Biosciences is proud to announce FDA clearance to initiate phase 2 study of DYV-700 for treatment of acute #gout pain. Full press release: tinyurl.com/qk4vtzm

@audieb70 Thanks Audra!

@DyveBio Congratulations!!

CEO Ryan Beal, MD chatted with @ModAesthetics about the latest research on Dyve's technology. Check out the full article: bit.ly/2OugRKK

When should lasers be used to treat #melasma? Mildred López Piñeiro, M.D. provides her insight in our new column on energy devices. buff.ly/2QqsUeJ

Dyve's SAB member Smitha Reddy, MD with CEO Ryan Beal, MD before Dr. Reddy's poster presentation at #ACR19 in Atlanta. For the complete poster, visit our publications page on our website: dyvebio.com/newsroom/publi…